Chemical Structure : PAICS inhibitor RLK
CAS No.:
2231428-32-1
PAICS inhibitor RLK
(Pubchem CID 135198613)
Catalog No.: PC-24716Not For Human Use, Lab Use Only.
PAICS inhibitor RLK is a specific, small molecule inhibitor of PAICS, an enzyme involved in de novo purine biosynthesis.
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
PAICS inhibitor RLK is a specific, small molecule inhibitor of PAICS, an enzyme involved in de novo purine biosynthesis.
PAICS inhibitor RLK inhibits tumor growth in vitro and in vivo by inhibiting PAICS activity.
Phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthetase (PAICS) catalyzes two essential steps in the de novo purine biosynthesis pathway.
PAICS is overexpressed in many cancers and could be a promising target for the development of cancer therapeutics.
Physicochemical Properties
|
M.Wt
|
515.43
|
|
Formula
|
C19H27BrN6O4S
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
2-amino-N-[2-bromo-5[-[4-3-(dimethylamino) propylsulfonyl] piperazin-1-yl] phenyl]-1,3-oxazole-4-carboxamide
|
References
1. Patent WO2018122549 A1.
2. Chamani R, et al. Iran J Biotechnol. 2025 Jan 1;23(1):e3935.
3. Škerlová J, et al. J Biol Chem. 2020; 295(33):11656-11668.
4. Simon Osborne, et al. Oxazole derivatives for use in the treatment of cancer, Patent US10961233B2, Compound 69.
Contact Us
sales@probechem.com
